Methods and compositions for inhibition of angiogenesis by thalidomide
US6235756A · kind A · utility
90Cited by
21References
24Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 22, 1997 |
| Grant date | May 22, 2001 |
| Priority date | — |
| Expiry date | Aug 22, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.